NovoCure (BSP:N2VC34) ROCE %: -45.84% (As of Mar. 2026)

What is NovoCure ROCE %?

NovoCure BSP:N2VC34 46 ROCE % is -45.84% as of Mar. 2026. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NovoCure's annualized ROCE % for the quarter that ended in Mar. 2026 was -45.84%.

NovoCure (BSP:N2VC34) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NovoCure ROCE % Related Terms

NovoCure ROCE % Historical Data

* Premium members only.

The historical data trend for NovoCure's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure ROCE % Chart

NovoCure Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-5.26

-7.45

-18.18

-19.16

-21.24

NovoCure Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-29.73	-30.96	-26.24	-4.02	-45.84

46GF Score

NovoCure Ltd BSP:N2VC34

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

NovoCure ROCE % Calculation

NovoCure's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-650.39	/	( ( (7570.023 - 4614.76)	+	(4388.161 - 1217.865) )	/ 2 )
	=	-650.39	/	( (2955.263	+	3170.296)	/ 2 )
	=	-650.39	/	3062.7795
	=	-21.24 %

NovoCure's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-1410.32	/	( ( (4388.161 - 1217.865)	+	(4120.538 - 1137.846) )	/ 2 )
	=	-1410.32	/	( ( 3170.296	+	2982.692 )	/ 2 )
	=	-1410.32	/	3076.494
	=	-45.84 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -45.84% mean?

NovoCure (BSP:N2VC34) has a ROCE % of -45.84% as of Mar. 2026.

Is NovoCure's ROCE % too high?

NovoCure's current ROCE % is -45.84%. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does NovoCure's ROCE % compare to NEOG and ESTA?

NovoCure's ROCE % of -45.84% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovoCure's current ROCE % is -45.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is NovoCure stock overvalued right now?

Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current ROCE % is -45.84%. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current ROCE % is -45.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (BSP:N2VC34) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for BSP:N2VC34:

ROCE %: -45.84%
GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies NEOG ESTA AXGN UFPT TMDX PRCT ALMR AHCO ENOV IART ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges NVCR:USA NVCRN:Mexico 038:Germany

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website https://www.novocure.com

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

46GF Score

Get the complete analysis for BSP:N2VC34

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$7.08

Price

R$8.98

GF Value

View BSP:N2VC34 Analysis

See ROCE % data for all stocks →